Clinical trials are research studies that are designed to determine if a medicine is safe and effective for patients. Patients may participate in ongoing clinical trials of Xencor’s investigational drug candidates if they meet certain enrollment criteria.
Condition: Acute Myelogenous Leukemia (AML); B-cell Acute Lymphoblastic Leukemia (B-ALL); Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Myeloid Leukemia (CML in blast phase)
Phase: Phase 1
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of vibecotamab and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
Conditions: B-cell Non-Hodgkin’s Lymphoma; Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Phase: Phase 1
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of plamotamab and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
Conditions: Neuroendocrine Tumor (NET); Gastrointestinal Neoplasm (GIST)
Phase: Phase 1
This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first “priming” dose and escalated subsequent doses of tidutamab; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of tidutamab in subjects with advanced NET or GIST.
Conditions: Melanoma; Breast Carcinoma; Hepatocellular Carcinoma (HCC); Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Colorectal Carcinoma (CRC); Non-small Cell Lung Carcinoma (NSCLC); Gastric or Gastroesophageal Junction Adenocarcinoma; Endometrial Carcinoma
Phase: Phase 1
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb717 in subjects with selected advanced solid tumors.
Conditions: Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma; Pancreatic Carcinoma; Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative (TNBC); Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Nasopharyngeal Carcinoma; Renal Cell Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Non-small Cell Lung Carcinoma; Small Cell Lung Cancer; Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Tumors
Phase: Phase 1
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb104 in subjects with selected advanced solid tumors.
Conditions: Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer (TNBC), Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors
Phase: Phase 1
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of
Conditions: Solid Tumors
Phase: Phase 1
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Conditions: Safety in Healthy Volunteers
Phase: Phase 1
This study will determine the safety and tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of XmAb564 in normal healthy volunteers. XmAb564 is an engineered IL-2 mutein being developed for autoimmune diseases.
Information about Xencor’s clinical trials is available at www.clinicaltrials.gov.
Xencor, Inc. Headquarters
111 West Lemon Avenue
Monrovia, CA 91016
(626) 305-5900
Xencor, Inc. San Diego
12481 High Bluff Dr., Suite 200
San Diego, CA 92130
(858) 617-6155